Cargando…

The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation

BACKGROUND: Diabetes is associated with premature death and a number of serious complications. The presence of comorbid depression makes these outcomes more likely and results in increased healthcare costs. The aim of this work was to assess the health economic outcomes associated with having both d...

Descripción completa

Detalles Bibliográficos
Autores principales: Kearns, Ben, Rafia, R., Leaviss, J., Preston, L., Brazier, J.E., Palmer, S., Ara, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259945/
https://www.ncbi.nlm.nih.gov/pubmed/28118838
http://dx.doi.org/10.1186/s12913-017-2003-z
_version_ 1782499308962054144
author Kearns, Ben
Rafia, R.
Leaviss, J.
Preston, L.
Brazier, J.E.
Palmer, S.
Ara, R.
author_facet Kearns, Ben
Rafia, R.
Leaviss, J.
Preston, L.
Brazier, J.E.
Palmer, S.
Ara, R.
author_sort Kearns, Ben
collection PubMed
description BACKGROUND: Diabetes is associated with premature death and a number of serious complications. The presence of comorbid depression makes these outcomes more likely and results in increased healthcare costs. The aim of this work was to assess the health economic outcomes associated with having both diabetes and depression, and assess the cost-effectiveness of potential policy changes to improve the care pathway: improved opportunistic screening for depression, collaborative care for depression treatment, and the combination of both. METHODS: A mathematical model of the care pathways experienced by people diagnosed with type-2 diabetes in England was developed. Both an NHS perspective and wider social benefits were considered. Evidence was taken from the published literature, identified via scoping and targeted searches. RESULTS: Compared with current practice, all three policies reduced both the time spent with depression and the number of diabetes-related complications experienced. The policies were associated with an improvement in quality of life, but with an increase in health care costs. In an incremental analysis, collaborative care dominated improved opportunistic screening. The incremental cost-effectiveness ratio (ICER) for collaborative care compared with current practice was £10,798 per QALY. Compared to collaborative care, the combined policy had an ICER of £68,017 per QALY. CONCLUSIONS: Policies targeted at identifying and treating depression early in patients with diabetes may lead to reductions in diabetes related complications and depression, which in turn increase life expectancy and improve health-related quality of life. Implementing collaborative care was cost-effective based on current national guidance in England. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12913-017-2003-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5259945
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52599452017-01-26 The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation Kearns, Ben Rafia, R. Leaviss, J. Preston, L. Brazier, J.E. Palmer, S. Ara, R. BMC Health Serv Res Research Article BACKGROUND: Diabetes is associated with premature death and a number of serious complications. The presence of comorbid depression makes these outcomes more likely and results in increased healthcare costs. The aim of this work was to assess the health economic outcomes associated with having both diabetes and depression, and assess the cost-effectiveness of potential policy changes to improve the care pathway: improved opportunistic screening for depression, collaborative care for depression treatment, and the combination of both. METHODS: A mathematical model of the care pathways experienced by people diagnosed with type-2 diabetes in England was developed. Both an NHS perspective and wider social benefits were considered. Evidence was taken from the published literature, identified via scoping and targeted searches. RESULTS: Compared with current practice, all three policies reduced both the time spent with depression and the number of diabetes-related complications experienced. The policies were associated with an improvement in quality of life, but with an increase in health care costs. In an incremental analysis, collaborative care dominated improved opportunistic screening. The incremental cost-effectiveness ratio (ICER) for collaborative care compared with current practice was £10,798 per QALY. Compared to collaborative care, the combined policy had an ICER of £68,017 per QALY. CONCLUSIONS: Policies targeted at identifying and treating depression early in patients with diabetes may lead to reductions in diabetes related complications and depression, which in turn increase life expectancy and improve health-related quality of life. Implementing collaborative care was cost-effective based on current national guidance in England. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12913-017-2003-z) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-24 /pmc/articles/PMC5259945/ /pubmed/28118838 http://dx.doi.org/10.1186/s12913-017-2003-z Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kearns, Ben
Rafia, R.
Leaviss, J.
Preston, L.
Brazier, J.E.
Palmer, S.
Ara, R.
The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation
title The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation
title_full The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation
title_fullStr The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation
title_full_unstemmed The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation
title_short The cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in England: a model-based economic evaluation
title_sort cost-effectiveness of changes to the care pathway used to identify depression and provide treatment amongst people with diabetes in england: a model-based economic evaluation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259945/
https://www.ncbi.nlm.nih.gov/pubmed/28118838
http://dx.doi.org/10.1186/s12913-017-2003-z
work_keys_str_mv AT kearnsben thecosteffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation
AT rafiar thecosteffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation
AT leavissj thecosteffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation
AT prestonl thecosteffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation
AT brazierje thecosteffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation
AT palmers thecosteffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation
AT arar thecosteffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation
AT kearnsben costeffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation
AT rafiar costeffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation
AT leavissj costeffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation
AT prestonl costeffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation
AT brazierje costeffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation
AT palmers costeffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation
AT arar costeffectivenessofchangestothecarepathwayusedtoidentifydepressionandprovidetreatmentamongstpeoplewithdiabetesinenglandamodelbasedeconomicevaluation